JPMorgan Upgrades Alkermes (ALKS) to Overweight. PT $78
- Wall Street ends higher, investors juggle Fed nerves with AI enthusiasm
- Apple in talks with Google to use generative AI in iPhones- Bloomberg
- World shares cheer China data, as central banks line up
- Oil prices climb 2% to 4-month high on lower Iraq, Saudi exports
- Meta Platforms is a new Top Pick at Mizuho, analyst sees upside to consensus
- After-hours movers: ANSYS, National CineMedia, and more
- Midday movers: Google, Pepsi rise; Boeing, Zillow fall
- Midday movers: Adobe, Zillow fall; Micron rises
- After-hours movers: Adobe Systems slumps; Rivian, Ulta Beauty gain
- Midday movers: Tesla, Nvidia fall premarket; Robinhood, Dollar General rise
Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder
October 20, 2016 4:00 PM EDTOnce-Daily ALKS 5461 Significantly Improved Depression Scores in Patients With Inadequate Response to Standard Antidepressant Therapies
Company to Request Meeting with FDA to Discuss Next Steps for Potential Regulatory Submission
Management to Hold Conference Call Today at 5:00 p.m. EDT
DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) today announced positive topline... More